Cardiovascular Consequences of Discontinuing Low-Do Chronic Coronary or Peripheral Artery Disease

Heart

107, 1130-1137

DOI: 10.1136/heartjnl-2020-318758

Citation Report

#	Article	IF	Citations
1	Early Stopping of a Randomised Trial for Efficacy: A Medical, Ethical and Regulatory Challenge. Heart, 2021, 107, 1109-1110.	4.9	2
2	Heartbeat: Is Postmenopausal Hormone Therapy a Risk Factor or Preventative Therapy for Cardiovascular Disease in Women?. Heart, 2021, 107, 1103-1105.	4.9	2
3	Prescribing of Low-Dose Rivaroxaban in Patients With Atherosclerotic Cardiovascular Disease in the United Kingdom and the Netherlands. British Journal of Clinical Pharmacology, 2023, 89, 2263-2271.	3.0	0
4	Trials Using Composite Outcomes Neglect the Presence of Competing Risks: A Methodological Survey of Cardiovascular Studies. Journal of Clinical Epidemiology, 2023, 160, 1-13.	4.9	8
5	Optimization of Secondary Prevention in Patients With High-Risk Atherothrombotic Ischemic Stroke or Transient Ischemic Attacks. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2023, 123, 36-43.	0.9	2
6	Antithrombotic Treatment in Coronary Artery Disease. Current Pharmaceutical Design, 2023, 29, 2764-2779.	3.4	4
7	Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?. Journal of Health Economics and Outcomes Research, 2024, 11, 154-160.	1.8	1
8	Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?. Journal of Health Economics and Outcomes Research, 2024, 11, 154-160.	1.8	0
9	Follow-Up and Pharmacological and Non-Pharmacological Important Decisions in Patients After Bypass Surgery. , 2026, .		0
10	Anticoagulation in Peripheral Artery Disease: Scoping Review With ❄SAIMSARA. , 2026, .		0
11	Clinical Profile, Management and Outcomes of Patients Taking Dual Pathway Inhibition for Cardiovascular Protection in Clinical Practice in Latin America. Data From the XATOA Registry. Drugs in Context, 2026, 15, 1.	2.5	0